These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16144950)

  • 1. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.
    Fehse F; Trautmann M; Holst JJ; Halseth AE; Nanayakkara N; Nielsen LL; Fineman MS; Kim DD; Nauck MA
    J Clin Endocrinol Metab; 2005 Nov; 90(11):5991-7. PubMed ID: 16144950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.
    Wajcberg E; Tavaria A
    Expert Opin Pharmacother; 2009 Jan; 10(1):135-42. PubMed ID: 19236187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.
    Hoelmkjaer KM; Wewer Albrechtsen NJ; Holst JJ; Cronin AM; Nielsen DH; Mandrup-Poulsen T; Bjornvad CR
    PLoS One; 2016; 11(5):e0154727. PubMed ID: 27136422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Type 2 diabetes: the role of incretin mimetics.
    Stonehouse AH; Holcombe JH; Kendall DM
    Expert Opin Pharmacother; 2006 Oct; 7(15):2095-105. PubMed ID: 17020435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide: its position in the treatment of type 2 diabetes.
    Guerci B; Martin CS
    Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes.
    Meneilly GS; Veldhuis JD; Elahi D
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6251-6. PubMed ID: 16091500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats.
    Gilor C; Graves TK; Gilor S; Ridge TK; Rick M
    Domest Anim Endocrinol; 2011 Jul; 41(1):42-9. PubMed ID: 21645806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
    Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K
    Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New drugs; exenatide and sitagliptin].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
    Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Exenatide--an alternative to insulin in the treatment of type 2 diabetes?].
    Kjeldsen R; Sandbaek A
    Ugeskr Laeger; 2008 Sep; 170(39):3039-43. PubMed ID: 18822227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide: a novel approach for treatment of type 2 diabetes.
    Mikhail N
    South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.